Our results suggested that combined chemotherapy and icotinib treatment tended to elicit a longer duration of DFS when compared with chemotherapy treatment alone in NSCLC patients with EGFR sensitive mutations, although the difference in DFS between the two treatment groups did not reach statistical significance (p = 0. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.